Patents by Inventor María BENLLOCH GARCÍA

María BENLLOCH GARCÍA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination comprising pterostilbene for the treatment of cancer
    Patent number: 11179348
    Abstract: The present invention relates to a combination comprising pterostilbeneor pterostilbene phosphate or a pharmaceutically acceptable salt thereof, a glutathione depleting agent and a cancer chemotherapeutic agent. The invention also relates to the medical use of this combination, in particular for the treatment and/or prevention of cancer.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: November 23, 2021
    Assignees: FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR, UNIVERSITAT DE VALÈNCIA—ESTUDI GENERAL, FUNDACIÓ INVESTIGACIÓ HOSPITAL GENERAL UNIVERSITARI DE VALÈNCIA PER A LA INVESTIGACIÓ BIOMÈDICA I CIÈNCIES DE LA SALUT, IDCQ HOSPITALES Y SANIDAD, S.L.U.
    Inventors: José María Estrela Arigüel, María Benlloch García, María Elena Plá Obrador, Lilian Soraya Vallés Martín, María Lucía Rodríguez Romero, Joan Antoni Sirerol Talens, Javier Luis Alcácer García, José Alfredo Pellicer Artés, Rosario Salvador Palmer, Guillermo María Sáez Tormo, Concepción Cerdá Micó
  • COMBINATION COMPRISING PTEROSTILBENE FOR THE TREATMENT OF CANCER
    Publication number: 20180214390
    Abstract: The present invention relates to a combination comprising pterostilbeneor pterostilbene phosphate or a pharmaceutically acceptable salt thereof, a glutathione depleting agent and a cancer chemotherapeutic agent. The invention also relates to the medical use of this combination, in particular for the treatment and/or prevention of cancer.
    Type: Application
    Filed: June 9, 2016
    Publication date: August 2, 2018
    Inventors: José María ESTRELA ARIGÜEL, María BENLLOCH GARCÍA, María Elena PLÁ OBRADOR, Lilian Soraya VALLÉS MARTÍN, María Lucía RODRÍGUEZ ROMERO, Joan Antoni SIREROL TALENS, Javier Luis ALCÁCER GARCÍA, José Alfredo PELLICER ARTÉS, Rosario SALVADOR PALMER, Guillermo María SÁEZ TORMO, Concepción CERDÁ MICÓ
  • Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments
    Patent number: 8227510
    Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER(20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: July 24, 2012
    Assignee: Universitat de Valencia
    Inventors: José María Estrela Ariquel, Gregorio Asensio Aguilar, Miguel Angel Asensi Miralles, Elena Obrador Plá, Maria Teresa Varea Muñoz, Leonardo Jordá Quilis, Paula Ferrer Pastor, Ramón Segarra Guerrero, Angel Ortega Valero, Maria Benlloch Garcia
  • COMBINE USE OF PTEROSTILBENE AND QUERCETIN FOR THE PRODUCTION OF CANCER TREATMENT MEDICAMENTS
    Publication number: 20110224290
    Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER (20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg×day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
    Type: Application
    Filed: July 19, 2005
    Publication date: September 15, 2011
    Inventors: José Maria Estrela Ariquel, Gregorio Asensio Aguilar, Miguel Angel Asensi Miralles, Elena Obrador Plá, Maria Teresa Varea Munoz, Leonardo Jordá Quilis, Paula Ferrer Pastor, Ramón Segarra Guerrero, Angel Ortega Valero, Maria Benlloch Garcia